Those who are allergic to peanut butter: rejoice. Allergy Therapeutics’ virus-like particle peanuts allergy candidate is about to enter Phase I trials, and the company has selected AGC Biologics to take on manufacturing duties.
SEATTLE – March 31, 2021 – AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced a new partnership with Allergy Therapeutics, the fully integrated specialty pharmaceutical company specializing in allergy vaccines. The CDMO has manufactured phase I clinical trial materials for Allergy Therapeutics’ novel virus-like particle (VLP)-based peanut allergy vaccine candidate (“VLP Peanut”), ahead of trial commencement later this year.
26 January 2022 Allergy Therapeutics (AIM: AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, today announces that the United States Food & Drug Administration (FDA) has cleared the Group’s Investigational New Drug application (IND) for its novel virus-like particle (VLP)-based peanut allergy vaccine candidate (“VLP Peanut”).
Allergy Therapeutics plc (LON:AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, has today announced the completion of treatment period of all patients in its exploratory field study (G309) to evaluate the efficacy and safety of Grass MATA MPL in subjects with seasonal allergic rhinitis and/or rhinoconjunctivitis induced by grass pollen. Grass MATA MPL is a short course, aluminium-free allergen-specific subcutaneous immunotherapy (SCIT) that aims to address the cause of symptoms of allergic rhinoconjunctivitis due to grass pollen.
WORTHING, UK I October 26, 2020 I Allergy Therapeutics plc (AIM: AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, today announces the screening of the first patient in its exploratory field study (G309) to evaluate the efficacy and safety of Grass MATA MPL in subjects with seasonal allergic rhinitis and/or rhinoconjunctivitis induced by grass pollen exposure. Grass MATA MPL is a short course, aluminium-free allergen-specific immunotherapy that aims to address the cause of symptoms of allergic rhinoconjunctivitis due to grass pollen.
09 July 2020 Allergy Therapeutics plc (AIM: AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, today is pleased to announce the outcome of scientific advice from the German Regulatory Authority, the Paul Ehrlich Institute (PEI), regarding invalidation of the primary endpoint data of the Birch MATA MPL pivotal Phase III clinical trial (B301).
Allergy Therapeutics announced positive Phase I safety and tolerability results of its subcutaneous Acarovac MPL (Monophosphoryl Lipid A). The results were in patients with house dust mite-induced allergic rhinoconjunctivitis.